respiratory assistance

NASDAQ: ISIS Provided an Update on Its Ongoing Open Label, Multiple Dose Phase 2 Study
Feb 27, 2014
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). To date, all four infants in the 6 mg cohort have been ...

Tags: ISIS, SMA, Infant, respiratory assistance